Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Arsenic Trioxide × Dermatologic × Clear all

Phase

Phase 1 2 Phase EARLY_PHASE1 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6 Plasma cell 4 Myeloid 3 Lymphoid 2 Sarcoma 1 Dermatologic 1 Classical hematology 1 CNS 1

Conditions

Skin Neoplasms 1 Carcinoma, Basal Cell 1

Interventions

pembrolizumab 72 Nivolumab 52 Ipilimumab 40 Cyclophosphamide 34 aldesleukin 26 Interleukin-2 22 fludarabine 16 Temozolomide 16 fludarabine phosphate 15 Biopsy 11 trametinib 10 dabrafenib 10 Radiotherapy 10 avelumab 8 Paclitaxel 8 Dacarbazine 8 Cisplatin 8 Bevacizumab 8 sargramostim 7 cemiplimab 7 lenvatinib 6 Magnetic Resonance Spectroscopy 6 Fluorouracil 6 spartalizumab 5 poly ICLC 5 montanide ISA 51 5 epacadostat 5 binimetinib 5 Vemurafenib 5 Specimen Handling 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01791894 2018-06-08

ATO

Stanford University

Phase 1/2 Completed

5 enrolled 9 charts

Carcinoma, Basal Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡